Tegavivint + Zanzalintinib for Liver Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to evaluate the combination of zanzalintinib (XL092) and tegavivint in advanced hepatocellular carcinoma (HCC) and Wnt pathway mutations who have progressed after at least one prior line of systemic therapy and are naïve (not previously treated with) standard of care tyrosine kinase inhibitors targeting vascular endothelial growth factor signaling.
Who Is on the Research Team?
David Hsieh, MD
Principal Investigator
University of Texas Southwestern Medical Center
Are You a Good Fit for This Trial?
This trial is for adults with advanced liver cancer (hepatocellular carcinoma) who have already tried at least one treatment but haven't received certain standard drugs called VEGF-targeting tyrosine kinase inhibitors. Participants should have specific gene changes in the Wnt pathway.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Tegavivint
- Zanzalintinib
Trial Overview
The study is testing a combination of two drugs, zanzalintinib and tegavivint, to see if they work together to treat advanced liver cancer. All participants will receive both medications.
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Phase 2, participants will be assigned to take zanzalintinib (XL092) and tegavivint at a dosage determine by Phase 1.
Participants will receive tegavivint as an intravenous infusion on Days 1, 8, 15, and 22 of each 28-day cycle at the dose level determined by the cohort assignment, combined with zanzalintinib 60 mg taken orally once daily on Days 1 through 28 of every cycle.
Starting Dose Level Participants will receive tegavivint as an intravenous infusion on Days 1, 8, 15, and 22 of each 28-day cycle at the dose level determined by the cohort assignment, combined with zanzalintinib 60 mg taken orally once daily on Days 1 through 28 of every cycle.
Participants will receive tegavivint as an intravenous infusion on Days 1, 8, 15, and 22 of each 28-day cycle at the dose level determined by the cohort assignment, combined with zanzalintinib 60 mg taken orally once daily on Days 1 through 28 of every cycle.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Texas Southwestern Medical Center
Lead Sponsor
Iterion Therapeutics
Industry Sponsor
Exelixis
Industry Sponsor
Michael M. Morrissey
Exelixis
Chief Executive Officer since 2010
PhD in Chemistry from Harvard University, BSc in Chemistry from the University of Wisconsin
Vicki L. Goodman
Exelixis
Chief Medical Officer since 2022
MD
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.